Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management

Key Points

• To update clinical practices for the diagnosis and management of marginal zone lymphoma (MZL).
• Reviewed frontline treatment strategies for localized and advanced-stage MZL.
• Analyzed the role of local therapies and systemic immunotherapy approaches.
• Considered emerging data on novel therapies including cBTKi and antibody-drug conjugates.
• Localized MZL favors local treatments like radiotherapy and rituximab monotherapy.
• Advanced-stage MZL typically requires systemic therapies including immunotherapy and chemotherapy.
• Emerging therapies such as cBTKi demonstrate potential in relapsed/refractory cases.

Abstract